This 35-year-old API manufacturing company exports to more than 86 countries with a customer base of over 1,200 worldwide. A publicly listed company headquartered in Mumbai, India, with annual sales exceeding USD 70 million, it manufactures generic APIs and advanced intermediates, with expertise in complex process chemistry from development to commercial scale establishing it as a leading CDMO partner. Its facility is accredited by various health regulatory agencies, including three USFDA approvals, two EU GMP/EDQM (Europe) approvals, KFDA (Korea), TGA (Australia), COFEPRIS (Mexico), SFDA-IDL (China), Halal, ISO and FAMI-QS certifications; as part of its business expansion plan, the company is doubling its reaction capacity by 2025 with a dedicated CDMO facility handling multiple API products from pilot scale to commercial supply, and is a leading world producer in therapeutic segments including antihistamines and anti-allergics.

No comments available.
Leave your rating & comment